Brokerages Set Novavax, Inc. (NASDAQ:NVAX) PT at $17.83

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has received a consensus rating of "Hold" from the six research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $17.83.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th.

Insider Transactions at Novavax

In other Novavax news, Director Rachel K. King sold 4,150 shares of Novavax stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the transaction, the director now owns 14,770 shares of the company's stock, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director James F. Young sold 5,400 shares of the business's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the sale, the director now directly owns 51,760 shares of the company's stock, valued at $414,080. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,150 shares of company stock worth $119,641. Company insiders own 1.00% of the company's stock.

Institutional Trading of Novavax

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Novavax by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company's stock valued at $126,439,000 after acquiring an additional 296,181 shares in the last quarter. Shah Capital Management lifted its holdings in shares of Novavax by 13.6% in the 4th quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company's stock worth $89,637,000 after acquiring an additional 1,333,305 shares during the last quarter. State Street Corp lifted its holdings in Novavax by 26.7% during the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company's stock worth $97,099,000 after buying an additional 1,621,772 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Novavax by 4.4% during the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company's stock worth $29,415,000 after buying an additional 155,206 shares in the last quarter. Finally, Bank of Montreal Can lifted its holdings in Novavax by 26.7% during the 3rd quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company's stock worth $32,643,000 after buying an additional 517,727 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company's stock.

Novavax Stock Up 0.1 %

NVAX stock traded up $0.01 during trading on Wednesday, hitting $8.19. 2,451,022 shares of the company's stock traded hands, compared to its average volume of 3,736,887. The firm has a market capitalization of $1.31 billion, a P/E ratio of -3.62, a PEG ratio of 63.06 and a beta of 2.14. The business has a fifty day simple moving average of $8.74 and a two-hundred day simple moving average of $10.25. Novavax has a 1 year low of $3.81 and a 1 year high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.07. The firm had revenue of $84.51 million during the quarter, compared to analysts' expectations of $65.80 million. During the same period in the prior year, the firm posted ($1.26) earnings per share. Novavax's revenue for the quarter was down 54.8% compared to the same quarter last year. On average, equities research analysts predict that Novavax will post -1.31 EPS for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.